18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 55, Issue 4, 2014, Pages 811-816

  Kahraman, Deniz ^a   Theurich, Sebastian ^a   Rothe, Achim ^a   Kuhnert, Georg ^a   Sasse, Stephanie ^a   Scheid, Christoph ^a   Dietlein, Markus ^a   Drzezga, Alexander ^a   Von Bergwelt Baildon, Michael ^a   Kobe, Carsten ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Brentuximab vedotin; FDG PET CT; Hodgkin lymphoma; Treatment response assessment

Indexed keywords

BRENTUXIMAB VEDOTIN; FLUORODEOXYGLUCOSE F 18; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CAC10-VCMMAE;

ADOLESCENT; ADULT; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HODGKIN DISEASE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; RATING SCALE; TREATMENT OUTCOME; TREATMENT RESPONSE; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; DIAGNOSTIC USE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLUORODEOXYGLUCOSE F18; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899478746     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.819575     Document Type: Article

References (21)

1. Engert A, Diehl V Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27: 4548-4554.
2. Diehl V Franklin J, Pfreundschuh M, et al. Standard and increased- dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-2395. (Pubitemid 36682817)
3. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantationfor relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359:2065-2071. (Pubitemid 34680969)
4. Moskowitz AJ, Perales MA, Kewalramani T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma.Br J Haematol 2009;146:158-163.
5. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-1821.
6. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-21899.
7. Zinzani PL, Rigacci L, Stefoni V, et al. Early interim 18F-FDG PETin Hodgkin's lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging 2012; 39: 4-12.
8. Le Roux PY, Gastinne T, Le Gouill S, et al. Prognostic value of interim FDG PET/CT in Hodgkin ' s lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging 2011;38:1064-1071.
9. MarkovaJ, KahramanD, KobeC, et al. Role of [18F] -fluoro-2-deoxy- D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leuk Lymphoma 2012;53:64-70. "
10. Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012; 119: 1665-1670.
11. Kasamon YL, Jacene HA, Gocke CD, et al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood 2012; 119: 4129-4132.
12. Younes A, Oki Y, McLaughlin P, et al. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 2012; 119: 4123-4128.
13. Meignan M, Gallamini A, Itti E, et al. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton2011 consensus. Leuk Lymphoma 2012;53:1876-1881.
14. Boellaard R.Need for standardization of 18F-FDG PET/CT for treatment response assessments. J Nucl Med 2011;52(Suppl.): 93S-100S.
15. Rothe A, Sasse S, Goergen H, et al. Brentuximab vedotin for relapsed or refractory CD30-positive hematologic malignancies: the GHSG experience. Blood 2012; 120: 1470-1472.
16. Theurich S, Malcher J, Wennhold K, et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma following allogeneic stem cell transplantation induces tumor specific immunity and sustained clinical remission. J Clin Oncol 2013; 31: e59-e63.
17. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586. (Pubitemid 350002966)
18. Kostakoglu L, Schoder H, Johnson JL, et al. Interim [(18)F] fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma 2012;53:2143-2150.
19. Furth C, Meseck RM, Steffen IG, et al. SUV-measurements and patient-specific corrections in pediatric Hodgkin-lymphoma: is there a benefit for PPV in early response assessment by FDG-PET? Pediatr Blood Cancer 2012; 59: 475-480.
20. Boellaard R, Krak NC, Hoekstra OS, et al. Effects ofnoise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study.J Nucl Med 2004; 45: 1519-1527. (Pubitemid 47618506)
21. Pregno P, Chiappella A, Bello M, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood 2012;119: 2066-2073.